|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: RHOV |
Gene summary for RHOV |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | RHOV | Gene ID | 171177 |
| Gene name | ras homolog family member V | |
| Gene Alias | ARHV | |
| Cytomap | 15q15.1 | |
| Gene Type | protein-coding | GO ID | GO:0006810 | UniProtAcc | A0A024R9R2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 171177 | RHOV | GSM4909281 | Human | Breast | IDC | 1.50e-07 | -3.28e-01 | 0.21 |
| 171177 | RHOV | GSM4909282 | Human | Breast | IDC | 1.73e-62 | 9.83e-01 | -0.0288 |
| 171177 | RHOV | GSM4909287 | Human | Breast | IDC | 1.06e-07 | -2.96e-01 | 0.2057 |
| 171177 | RHOV | GSM4909293 | Human | Breast | IDC | 1.21e-02 | -2.61e-01 | 0.1581 |
| 171177 | RHOV | GSM4909294 | Human | Breast | IDC | 2.00e-03 | -2.94e-01 | 0.2022 |
| 171177 | RHOV | GSM4909296 | Human | Breast | IDC | 3.36e-04 | -1.55e-01 | 0.1524 |
| 171177 | RHOV | GSM4909297 | Human | Breast | IDC | 4.92e-04 | -1.40e-01 | 0.1517 |
| 171177 | RHOV | GSM4909300 | Human | Breast | IDC | 9.64e-04 | 4.51e-01 | 0.0334 |
| 171177 | RHOV | GSM4909301 | Human | Breast | IDC | 3.84e-14 | -3.89e-01 | 0.1577 |
| 171177 | RHOV | GSM4909302 | Human | Breast | IDC | 9.01e-06 | -3.06e-01 | 0.1545 |
| 171177 | RHOV | GSM4909304 | Human | Breast | IDC | 8.45e-09 | -3.59e-01 | 0.1636 |
| 171177 | RHOV | GSM4909306 | Human | Breast | IDC | 3.98e-02 | 2.50e-01 | 0.1564 |
| 171177 | RHOV | GSM4909311 | Human | Breast | IDC | 2.21e-16 | -2.64e-01 | 0.1534 |
| 171177 | RHOV | GSM4909312 | Human | Breast | IDC | 6.91e-08 | -2.75e-01 | 0.1552 |
| 171177 | RHOV | GSM4909315 | Human | Breast | IDC | 1.32e-06 | -3.17e-01 | 0.21 |
| 171177 | RHOV | GSM4909319 | Human | Breast | IDC | 1.54e-18 | -3.56e-01 | 0.1563 |
| 171177 | RHOV | GSM4909320 | Human | Breast | IDC | 2.01e-06 | -4.11e-01 | 0.1575 |
| 171177 | RHOV | GSM4909321 | Human | Breast | IDC | 2.23e-07 | -1.99e-01 | 0.1559 |
| 171177 | RHOV | brca2 | Human | Breast | Precancer | 2.09e-19 | 5.69e-01 | -0.024 |
| 171177 | RHOV | M1 | Human | Breast | IDC | 7.54e-08 | -3.96e-01 | 0.1577 |
| Page: 1 2 3 4 5 6 7 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Breast |  | IDC: Invasive ductal carcinoma |
| DCIS: Ductal carcinoma in situ | ||
| Precancer(BRCA1-mut): Precancerous lesion from BRCA1 mutation carriers | ||
| Cervix |  | CC: Cervix cancer |
| HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions | ||
| N_HPV: HPV-infected normal cervix | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Lung |  | AAH: Atypical adenomatous hyperplasia |
| AIS: Adenocarcinoma in situ | ||
| IAC: Invasive lung adenocarcinoma | ||
| MIA: Minimally invasive adenocarcinoma | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:00072656 | Cervix | CC | Ras protein signal transduction | 79/2311 | 337/18723 | 9.49e-09 | 7.77e-07 | 79 |
| GO:00072666 | Cervix | CC | Rho protein signal transduction | 35/2311 | 137/18723 | 1.77e-05 | 3.33e-04 | 35 |
| GO:000726510 | Esophagus | ESCC | Ras protein signal transduction | 201/8552 | 337/18723 | 1.44e-07 | 2.30e-06 | 201 |
| GO:000726610 | Esophagus | ESCC | Rho protein signal transduction | 81/8552 | 137/18723 | 1.03e-03 | 5.20e-03 | 81 |
| GO:000726521 | Liver | HCC | Ras protein signal transduction | 187/7958 | 337/18723 | 8.89e-07 | 1.35e-05 | 187 |
| GO:000726621 | Liver | HCC | Rho protein signal transduction | 76/7958 | 137/18723 | 1.46e-03 | 7.75e-03 | 76 |
| GO:00072655 | Lung | IAC | Ras protein signal transduction | 65/2061 | 337/18723 | 4.48e-06 | 1.81e-04 | 65 |
| GO:00072665 | Lung | IAC | Rho protein signal transduction | 32/2061 | 137/18723 | 2.75e-05 | 7.26e-04 | 32 |
| GO:00072659 | Oral cavity | OSCC | Ras protein signal transduction | 185/7305 | 337/18723 | 1.95e-09 | 4.60e-08 | 185 |
| GO:00072669 | Oral cavity | OSCC | Rho protein signal transduction | 76/7305 | 137/18723 | 6.64e-05 | 5.37e-04 | 76 |
| GO:000726515 | Oral cavity | LP | Ras protein signal transduction | 109/4623 | 337/18723 | 8.44e-04 | 7.36e-03 | 109 |
| GO:000726522 | Oral cavity | EOLP | Ras protein signal transduction | 74/2218 | 337/18723 | 8.76e-08 | 3.09e-06 | 74 |
| GO:000726615 | Oral cavity | EOLP | Rho protein signal transduction | 29/2218 | 137/18723 | 1.28e-03 | 9.16e-03 | 29 |
| GO:000726516 | Skin | AK | Ras protein signal transduction | 68/1910 | 337/18723 | 2.83e-08 | 1.57e-06 | 68 |
| GO:000726616 | Skin | AK | Rho protein signal transduction | 31/1910 | 137/18723 | 1.60e-05 | 3.09e-04 | 31 |
| GO:000726523 | Skin | cSCC | Ras protein signal transduction | 132/4864 | 337/18723 | 6.17e-08 | 1.57e-06 | 132 |
| GO:000726617 | Skin | cSCC | Rho protein signal transduction | 51/4864 | 137/18723 | 2.38e-03 | 1.38e-02 | 51 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| RHOV | SNV | Missense_Mutation | c.244N>C | p.Glu82Gln | p.E82Q | Q96L33 | protein_coding | tolerated(1) | benign(0.006) | TCGA-C5-A1MF-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD | |
| RHOV | SNV | Missense_Mutation | novel | c.485N>T | p.Arg162Leu | p.R162L | Q96L33 | protein_coding | deleterious(0.03) | possibly_damaging(0.499) | TCGA-DS-A7WI-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | PD |
| RHOV | SNV | Missense_Mutation | novel | c.277N>T | p.Asp93Tyr | p.D93Y | Q96L33 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-D5-6923-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| RHOV | SNV | Missense_Mutation | c.448N>A | p.Asp150Asn | p.D150N | Q96L33 | protein_coding | tolerated(0.09) | possibly_damaging(0.576) | TCGA-A5-A0G2-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | |
| RHOV | SNV | Missense_Mutation | c.536N>A | p.Arg179Gln | p.R179Q | Q96L33 | protein_coding | tolerated(0.1) | benign(0.273) | TCGA-AP-A056-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| RHOV | SNV | Missense_Mutation | rs775096024 | c.388C>T | p.Arg130Cys | p.R130C | Q96L33 | protein_coding | deleterious(0.01) | probably_damaging(0.989) | TCGA-AX-A2HC-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | PD |
| RHOV | SNV | Missense_Mutation | novel | c.683N>A | p.Arg228His | p.R228H | Q96L33 | protein_coding | tolerated(0.12) | possibly_damaging(0.508) | TCGA-AX-A2HD-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
| RHOV | SNV | Missense_Mutation | novel | c.556N>C | p.Cys186Arg | p.C186R | Q96L33 | protein_coding | deleterious(0) | probably_damaging(0.997) | TCGA-DD-AADN-01 | Liver | liver hepatocellular carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| RHOV | SNV | Missense_Mutation | novel | c.491N>A | p.Gly164Asp | p.G164D | Q96L33 | protein_coding | tolerated(0.06) | benign(0.021) | TCGA-21-1079-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Unknown | Unknown | PD |
| RHOV | SNV | Missense_Mutation | novel | c.526N>A | p.Glu176Lys | p.E176K | Q96L33 | protein_coding | tolerated(0.74) | benign(0.026) | TCGA-CQ-5333-01 | Oral cavity | head & neck squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | PD |
| Page: 1 2 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |